DXCM vs EBS · P/E 63, rev $4.03B vs rev $1.04B
DexCom Inc (DXCM) versus Emergent Biosolutions Inc (EBS) — a side-by-side from cached financials, not a winner call.
DexCom Inc (DXCM) is a medical devices company listed on US.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported DXCM revenue for 2024-12-31 was $4.03B. Net income was $576.2M. Revenue was up 11.3% from 2023-12-31 to 2024-12-31. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
Latest reported EBS revenue for 2024-12-31 was $1.04B. Net income was -$190.6M. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. EBS currently screens at market cap $416.4M.
DXCM currently screens at market cap $32.84B and trailing P/E 62.5. EBS currently screens at market cap $416.4M.
Not investment advice. Open the DXCM and EBS stock pages for the full models.
Not investment advice.